CEO interview reveals $ACOG's 2022 plan (human trials etc.) CEO of Alpha Cognition ( $ACOG.V $ ACOGF ) Michael McFadden went on the
Radius Research YT channel to speak on the results from $ACOG's Alpha-1062 Traumatic Brain Injury study.
Some McFadden's main points:
- Alpha-1062 was able to get mice with TBIs to cognitively perform at the same level as uninjured mice.
- Getting results as good as they got is rare for these early tests (very promising).
- In Q1 2022 they will be releasing autopsy results from the mice to see how the brains of the injured/uninjured and treated/untreated mice compare.
- After this, they will be having a meeting with the FDA to see if they need to do a 2nd round of animal trials or if they can move into human testing
- Because there is a high treatment need for TBIs but currently no treatments on the market the FDA may expedite the trial process of Alpha-1062 (i.e. less human trials needed before it goes on the market)
- & more
Check out the full interview here
$ACOG @ $1.12, MC $68.876M